On the stock market since 2018, it operates in the world of heavy industry. It has 593 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
The biggest line carries real weight, but it doesn’t decide everything on its own.
An average decline of 21% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 90% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $293.2M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 25 buys and 3 sells. Management buying with its own money is usually read as a good sign.
A loss of $128.1M against $293.2M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, CHRA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CHRA is a high-risk stock — not yet profitable, and its future rides on its product catching on.